B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to severe atopic dermatitis and have completed a qualifying parent study. The efficacy and safety of two dosage strengths of Abrocitinib, 100 mg and 200 mg taken orally once daily, will be evaluated over variable lengths of study participation. The study consists of a 92 week initial treatment period followed by a variable length secondary treatment period during which subjects will receive treatment with open-label abrocitinib until availability of commercial product in their country, or until the sponsor terminates the study in that country.

The B7451015 study also includes a sub-study evaluating whether abrocitinib has any potential effects on adolescent bone with regard to abnormal bone findings in knee MRI. The sub-study will be conducted in selected countries at selected sites. Eligible subjects are those who were 12 to \<18 years of age at the screening visit of the qualifying parent study and who are currently participating in the main B7451015 study. The sub-study will include serial Magnetic Resonance Imaging (MRI) annually and continue until all enrolled subjects are 18 years of age and have been imaged at least once or have discontinued/withdrawn.

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Greensboro - Cardiology

Shelby, NC

Norfolk, VA

Rockville, MD

White Marsh, MD

Bexley, OH

Forest Hills Dermatology Group

Jacksonville, FL

Owensboro, KY

Indianapolis, IN

Plainfield, IN

UR Dermatology at College Town

London, Canada

Derm Center

Troy, MI

Oakvile, Canada

Mississauga, Canada

Clarkston, MI

Toronto, Canada

Ontario, Canada

Richmond Hill, Canada

Ontario, CA

Barrie, Canada

Tampa, FL

Normal, IL

Boca Raton, FL

Miami Lakes, FL

Clinical Research Site

Clinical Operations Department

Miami, FL

Sudbury, Canada

Clinique Medicale Saint-Louis

Saint Joseph, MO

Minneapolis, MN

Arlington, TX

Pflugerville, TX

San Antonio, Texas

Merida, Mexico

San Antonio, TX

Rapid City, SD

Monterrey, Mexico

St. Johns, NL

Veracruz, Mexico

JM Research SC

Calgary, Canada

Edmonton, AB

Spokane, WA

San Diego, CA

Encinitas, CA

HQ, Irvine, CA

Fountain Valley, CA

Santa Monica, CA

Portland, OR

Sheffield Children's Hospital - Clinical Research Facility

Clinical Research Unit

Luigi Sacco University Hospital - Gastroenterology and Digestive Endoscopy Department

Wroclaw, Poland

Krakow, Poland

Maroubra

East Melbourne, Australia

Carlton, Australia

Pfizer

Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Galderma

Find clinical trials for Eczema in Durham, NC

Related conditions:

Eczema trials near Durham, NC, USA:

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (JADE EXTEND)

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Find clinical trials for Eczema in .css-epvm6{white-space:nowrap;}Durham, NC

Related conditions:

Eczema trials near Durham, NC, USA:

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (JADE EXTEND)

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Find clinical trials for Eczema in Durham, NC